Condition: Gastroenterology · LARS - Low Anterior Resection Syndrome · Rectal Cancer · Sponsor: Qufora A/S
The purpose of this post-market clinical follow up study is to assess the efficacy on clinical symptoms of LARS of low volume Transanal Irrigation by MiniGo in conjunction with conservative treatment versus conservative treatment at 3 months.
This description comes directly from the study's public registry record.
Rogini Balachandran · + 45 42 40 06 20 · rob@qufora.com
Always discuss trial participation with your own doctor first.
| CHU Amiens-Picardie | Amiens, France | Recruiting |
| CHU Besançon | Besançon, France | Recruiting |
| Clinique Tivoli-Ducos | Bordeaux, France | Recruiting |
| CHU Grenoble | La Tronche, France | Recruiting |
| CHU Timone | Marseille, France | Not Yet Recruiting |
| CHU de NANTES, Hôtel Dieu | Nantes, France | Recruiting |
| CHU Bordeaux, GH Sud, Hôpital HAUT-LEVEQUE | Pessac, France | Not Yet Recruiting |
| CH Lyon Sud | Pierre-Bénite, France | Not Yet Recruiting |
| CHU Charles Nicolle - Rouen | Rouen, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06923150